B

BioAtla
D

BCAB

3.35000
USD
0.09
(2.76%)
مغلق
حجم التداول
38
الربح لكل سهم
-2
العائد الربحي
-
P/E
-0
حجم السوق
5,559,506
المقالات
المزيد

العنوان: BioAtla Inc.

القطاع: الرعاية الصحية
الصناعة: Biotechnology
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs. The company's operations are organized on a single reportable segment, which includes all activities related to the discovery, development, and commercialization of its CAB products.